Catalent has unveiled plans to invest up to $40 million at its manufacturing facility in Winchester, KY. The investment will see the installation of new equipment that will increase the site’s formulation and controlled-release tablet and capsule manufacturing capabilities, and capacity.
 
New technologies that are included in the investment include a laser drill for osmotic drug delivery, stick pack dosage manufacturing capabilities, and roller compaction and fluid bed capacity will be increased at the site. Additionally, a spray dryer, used to create amorphous solid dispersions and overcome formulation challenges posed by poorly soluble drugs, will be installed to provide commercial scale up capacity for projects that progress from early stage development, and allow tech transfer of projects from Catalent’s development sites including San Diego, CA and Nottingham, UK.
 
An automated bottling line is also currently being installed, and completion of the various equipment validations is expected over the coming months.
 
“Our Winchester facility provides customers with a high degree of flexible manufacturing solutions and has a proven track record of success with technology transfers and product launches,” said Rick Tucker, general manager, Catalent Winchester. “We have a clear investment strategy at the site that is not only driven by immediate customer needs, but also looks to the future in anticipation of demand and new technologies.”
 
Opened in 1992, Catalent’s Winchester facility has evolved into one of the industry’s premier sites for advanced oral controlled-release drug formulation and manufacturing. The site has produced over three-billion tablets and capsules annually and launched more than 100 new products into the market since its inception. The site underwent a $35 million facility investment in 2015 that doubled its footprint to 180,000 square feet.

Catalent is exhibiting at CPhI North America at booth 1206.